NEJM significant progress! The COVID-19 vaccine mRNA-1273 produces high-titer neutral antibodies and is safe.

July 16, 2020 // According to interim results published online in the New England Journal of Medicine, a vaccine mRNA-1273, a vaccine designed to prevent 2019 coronavirus (COVID-19), has good resistance and neutralizing antibody activity in healthy adultsThe first phase of the trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of HealthThe experimental vaccine was developed by researchers from NIAID and Moderna in Cambridge, MassachusettsMRNA-1273, manufactured by Moderna, is designed to induce neutralizing antibodies that point to part of the coronavirus "sting" protein, which binds and enters human cells using a stingproteinPhoto source; The NIAID trial was led by Lisa AJackson, M.D., M.D., Public Health, at the Kaiser Permanente Washington Institute of Health, where the first participants received a candidate for the vaccine on March 16The interim report details the initial findings of 45 participants between the ages of 18 and 55 who participated in the study at Emory University in Seattle and AtlantaThe study was planned to give three groups of 15 participants two intramuscular injections, 28 days apart, for 25,100 or 250 micrograms of the study vaccineAll participants received the first injection; In April, the trial was expanded to adults over the age of 55; However, the latest results only cover people aged 18 to 55In terms of security, no serious adverse events have been reportedMore than half of the participants reported fatigue, headache, chills, myalgia, or pain at the injection siteSystemic adverse events are more common in people who are vaccinated for the second time and receive the highest dose of the vaccineData on side effects and immune responses in various vaccine doses provide a basis for the use or planned use of doses in phase II and III clinical trials of research vaccinesThe interim analysis included the results of a trial that measured the neutralized and active levels of the vaccine induction on the 43rd day after the second injectionTwo doses of the vaccine promoted high levels of neutralizing antibody activity, which was higher than the average seen in the recovery period serum obtained from confirmed PATIENTs with COVID-19The Phase II clinical trial of mRNA-1273, sponsored by Moderna, began at the end of MayPhase III efficacy trials are planned to be launched in July 2020 () References: EcicoVID-19 Vaccine safe, generates immune responseLisa A Jackson et al, an mRNA Vaccine against SARS-CoV-2-Preliminary Report, New England Of Medicine (2020) DOI: 10.1056/NEJMoa2022483.